Biosimulation Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

Biosimulation, a technique harnessing computer programs to simulate biological processes, is revolutionizing the field of drug discovery and development. This innovative tool allows researchers to predict the outcomes of experiments related to drug development, significantly reducing the risk of late-stage drug failures and the associated waste of resources.

The global biosimulation market is poised for significant growth with a strong compound annual growth rate (CAGR) anticipated during the assessment period, leading to substantial market size expansion by 2031.

North America Takes the Lead

In terms of value, North America is poised to dominate the global biosimulation market throughout the assessment period. With a strong CAGR, North America remains the most attractive market for biosimulation, reflecting its substantial investment in healthcare and advanced software technology related to simulation.

Software Product Type Segment Thrives

The software product category is projected to achieve substantial growth by 2031, demonstrating a strong compound annual growth rate (CAGR) between 2024 and 2031. In 2023, this segment held the majority of the market's revenue share, representing almost two-thirds, and is expected to maintain a significant presence, albeit with a slight decline in market share by 2031.

Key Players Driving Innovation

The global biosimulation market is seeing active participation from companies at the forefront of innovation. Leading firms such as Certara, L.P., Simulations Plus, Inc., Dassault Systemes SE, Schrodinger, Inc., Advanced Chemistry Development, Inc., Entelos, Inc., Evidera, Inc., Genedata AG, Leadscope Inc., and Acceryls Inc. are expected to continue driving the market's expansion through 2031.

As the drug discovery and development process becomes increasingly costly and resource-intensive, biosimulation emerges as a crucial predictive tool, helping researchers make informed decisions and improve the efficiency of the drug development pipeline.

Biosimulation Market Segmentation

Product

Software
Services

End User

Academic and Government Research Institutes
Pharmaceutical and Biotech Companies
Contract Research Organizations
Regulatory Authorities
Other End Users

Application

Drug Development
Drug Discovery
Other Applications

Region

North America
Latin America
Europe
Japan
Asia Pacific excluding Japan
Middle East and Africa

1. Executive Summary

1.1. Global Biosimulation Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Biosimulation Market Outlook, 2018 - 2031

3.1. Global Biosimulation Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Software
  - 3.1.1.2. Services
3.2. Global Biosimulation Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Drug Development
  - 3.2.1.2. Drug Discovery
  - 3.2.1.3. Other Applications
3.3. Global Biosimulation Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Academic and Government Research Institutes
  - 3.3.1.2. Pharmaceutical and Biotech Companies
  - 3.3.1.3. Contract Research Organizations
  - 3.3.1.4. Regulatory Authorities
  - 3.3.1.5. Other End Users
3.4. Global Biosimulation Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. North America
  - 3.4.1.2. Europe
  - 3.4.1.3. Asia Pacific
  - 3.4.1.4. Latin America
  - 3.4.1.5. Middle East & Africa

4. North America Biosimulation Market Outlook, 2018 - 2031

4.1. North America Biosimulation Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Software
  - 4.1.1.2. Services
4.2. North America Biosimulation Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Drug Development
  - 4.2.1.2. Drug Discovery
  - 4.2.1.3. Other Applications
4.3. North America Biosimulation Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Academic and Government Research Institutes
  - 4.3.1.2. Pharmaceutical and Biotech Companies
  - 4.3.1.3. Contract Research Organizations
  - 4.3.1.4. Regulatory Authorities
  - 4.3.1.5. Other End Users
4.4. North America Biosimulation Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. U.S. Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 4.4.1.2. U.S. Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 4.4.1.3. U.S. Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
  - 4.4.1.4. Canada Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 4.4.1.5. Canada Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 4.4.1.6. Canada Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
- 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Biosimulation Market Outlook, 2018 - 2031

5.1. Europe Biosimulation Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Software
  - 5.1.1.2. Services
5.2. Europe Biosimulation Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Drug Development
  - 5.2.1.2. Drug Discovery
  - 5.2.1.3. Other Applications
5.3. Europe Biosimulation Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Academic and Government Research Institutes
  - 5.3.1.2. Pharmaceutical and Biotech Companies
  - 5.3.1.3. Contract Research Organizations
  - 5.3.1.4. Regulatory Authorities
  - 5.3.1.5. Other End Users
5.4. Europe Biosimulation Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Germany Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.2. Germany Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.3. Germany Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.4. U.K. Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.5. U.K. Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.6. U.K. Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.7. France Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.8. France Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.9. France Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.10. Italy Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.11. Italy Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.12. Italy Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.13. Turkey Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.14. Turkey Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.15. Turkey Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.16. Russia Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.17. Russia Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.18. Russia Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.19. Rest of Europe Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.20. Rest of Europe Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.21. Rest of Europe Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
- 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Biosimulation Market Outlook, 2018 - 2031

6.1. Asia Pacific Biosimulation Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Software
  - 6.1.1.2. Services
6.2. Asia Pacific Biosimulation Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Drug Development
  - 6.2.1.2. Drug Discovery
  - 6.2.1.3. Other Applications
6.3. Asia Pacific Biosimulation Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Academic and Government Research Institutes
  - 6.3.1.2. Pharmaceutical and Biotech Companies
  - 6.3.1.3. Contract Research Organizations
  - 6.3.1.4. Regulatory Authorities
  - 6.3.1.5. Other End Users
6.4. Asia Pacific Biosimulation Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. China Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.2. China Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.3. China Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
  - 6.4.1.4. Japan Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.5. Japan Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.6. Japan Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
  - 6.4.1.7. South Korea Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.8. South Korea Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.9. South Korea Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
  - 6.4.1.10. India Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.11. India Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.12. India Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
  - 6.4.1.13. Southeast Asia Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.14. Southeast Asia Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.15. Southeast Asia Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
  - 6.4.1.16. Rest of Asia Pacific Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.17. Rest of Asia Pacific Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.18. Rest of Asia Pacific Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
- 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Biosimulation Market Outlook, 2018 - 2031

7.1. Latin America Biosimulation Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Software
  - 7.1.1.2. Services
7.2. Latin America Biosimulation Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Drug Development
  - 7.2.1.2. Drug Discovery
  - 7.2.1.3. Other Applications
7.3. Latin America Biosimulation Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Academic and Government Research Institutes
  - 7.3.1.2. Pharmaceutical and Biotech Companies
  - 7.3.1.3. Contract Research Organizations
  - 7.3.1.4. Regulatory Authorities
  - 7.3.1.5. Other End Users
7.4. Latin America Biosimulation Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Brazil Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.2. Brazil Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 7.4.1.3. Brazil Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
  - 7.4.1.4. Mexico Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.5. Mexico Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 7.4.1.6. Mexico Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
  - 7.4.1.7. Argentina Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.8. Argentina Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 7.4.1.9. Argentina Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
  - 7.4.1.10. Rest of Latin America Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.11. Rest of Latin America Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 7.4.1.12. Rest of Latin America Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
- 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Biosimulation Market Outlook, 2018 - 2031

8.1. Middle East & Africa Biosimulation Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Software
  - 8.1.1.2. Services
8.2. Middle East & Africa Biosimulation Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Drug Development
  - 8.2.1.2. Drug Discovery
  - 8.2.1.3. Other Applications
8.3. Middle East & Africa Biosimulation Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Academic and Government Research Institutes
  - 8.3.1.2. Pharmaceutical and Biotech Companies
  - 8.3.1.3. Contract Research Organizations
  - 8.3.1.4. Regulatory Authorities
  - 8.3.1.5. Other End Users
8.4. Middle East & Africa Biosimulation Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. GCC Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.2. GCC Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.3. GCC Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
  - 8.4.1.4. South Africa Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.5. South Africa Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.6. South Africa Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
  - 8.4.1.7. Egypt Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.8. Egypt Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.9. Egypt Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
  - 8.4.1.10. Nigeria Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.11. Nigeria Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.12. Nigeria Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
  - 8.4.1.13. Rest of Middle East & Africa Biosimulation Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.14. Rest of Middle East & Africa Biosimulation Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.15. Rest of Middle East & Africa Biosimulation Market End User, Value (US$ Bn), 2018 - 2031
- 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Product vs End User Heatmap
9.2. Manufacturer vs End User Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
- 9.5.1. Certara, L.P
  - 9.5.1.1. Company Overview
  - 9.5.1.2. Product Portfolio
  - 9.5.1.3. Financial Overview
  - 9.5.1.4. Business Strategies and Development
- 9.5.2. Simulations Plus, Inc.
  - 9.5.2.1. Company Overview
  - 9.5.2.2. Product Portfolio
  - 9.5.2.3. Financial Overview
  - 9.5.2.4. Business Strategies and Development
- 9.5.3. Dassault Systemes SE
  - 9.5.3.1. Company Overview
  - 9.5.3.2. Product Portfolio
  - 9.5.3.3. Financial Overview
  - 9.5.3.4. Business Strategies and Development
- 9.5.4. Schrodinger, Inc
  - 9.5.4.1. Company Overview
  - 9.5.4.2. Product Portfolio
  - 9.5.4.3. Financial Overview
  - 9.5.4.4. Business Strategies and Development
- 9.5.5. Advanced Chemistry Development, Inc.
  - 9.5.5.1. Company Overview
  - 9.5.5.2. Product Portfolio
  - 9.5.5.3. Financial Overview
  - 9.5.5.4. Business Strategies and Development
- 9.5.6. Entelos, Inc.
  - 9.5.6.1. Company Overview
  - 9.5.6.2. Product Portfolio
  - 9.5.6.3. Financial Overview
  - 9.5.6.4. Business Strategies and Development
- 9.5.7. Evidera, Inc.
  - 9.5.7.1. Company Overview
  - 9.5.7.2. Product Portfolio
  - 9.5.7.3. Financial Overview
  - 9.5.7.4. Business Strategies and Development
- 9.5.8. Genedata AG
  - 9.5.8.1. Company Overview
  - 9.5.8.2. Product Portfolio
  - 9.5.8.3. Financial Overview
  - 9.5.8.4. Business Strategies and Development
- 9.5.9. Leadscope Inc
  - 9.5.9.1. Company Overview
  - 9.5.9.2. Product Portfolio
  - 9.5.9.3. Financial Overview
  - 9.5.9.4. Business Strategies and Development
- 9.5.10. Acceryls Inc.
  - 9.5.10.1. Company Overview
  - 9.5.10.2. Product Portfolio
  - 9.5.10.3. Financial Overview
  - 9.5.10.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations